NCT00582738View on ClinicalTrials.gov

Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection

PHASE2TerminatedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Recurrent Hepatitis C
Interventions
DRUG

CsA-TAC (standard Treatment)

Continuation of current immunosuppressive regimen (continuation of CNI with or without MPA, with or without steroids) / no everolimus introduction.

DRUG

Everolimus

Hepatitis C recurrence after orthotopic liver transplantation (OLT)

Trial Locations (1)

Unknown

Novartis Investigative site, Buenos Aires

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY